Abstract 428P
Background
Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm with an intermediate biologic potential. The aim of this study was to investigate clinical and pathological factors as well as peripheral blood counts to determine factors predicting for likelihood of early recurrence and poor survival in extra-meningeal SFTs after surgical resection.
Methods
We retrieved the records of 101 patients that were consecutively diagnosed with SFT from 1996-2019 at the National Cancer Centre Singapore and Singapore General Hospital. 19 patients were excluded from the study, of which 6 had distant metastasis at diagnosis, 5 did not undergo curative surgery and 8 were meningeal SFTs that are known to have a poor prognosis. The remaining 82 cases of extra-meningeal SFTs that underwent curative surgery were retrospectively examined with survival analyses performed using the Kaplan-Meier method and multivariate Cox proportional models.
Results
The cohort consisted of 37 men and 45 women with a median age of 51 years (range, 13-87). The primary site of the tumour was abdominopelvic in 18 (22.0%), limbs/trunk in 27 (32.9%), pulmonary/pleura in 18 (22.0%) and head/neck in 19 (23.2%). Median tumour size was 5.0 cm (range, 1.4-30.0). The 5-year overall survival (OS) and event-free survival (EFS) was 92.4% and 79.2% respectively. On univariate analysis, advanced age was prognostic for worse OS, while an abdominopelvic site, lymphocytosis (>2.2 x 109/L) and monocytosis (>0.56 x 109/L) were prognostic for both worse OS and EFS. On multivariate analysis, only age, abdominopelvic site and monocytosis remained independently prognostic for OS, while abdominopelvic site and monocytosis were retained as independently prognostic factors for EFS (all p < 0.05). Tumour depth, tumour size, resection margin, tumour necrosis and mitotic count were not significantly prognostic.
Conclusions
In extra-meningeal SFT, clinical factors including advanced age and abdominopelvic location indicate poor prognosis. In addition, peripheral monocytosis at diagnosis may serve as a novel and easily obtained biomarker for further prognostication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Centre Singapore.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session